Skip to main content

Eikon Therapeutics, Inc.

corporate_fare Company Profile

Eikon Therapeutics, Inc.

EIKN·NASDAQ·Life Sciences·CIK 0001861123

Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company building a global, fully-integrated organization to develop innovative medicines addressing serious unmet medical needs. Its initial focus is oncology, where it is advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. The company's strategy centers on deploying its technology platform, including its proprietary single molecule tracking (SMT) system, to develop internally-derived novel therapies, while also leveraging its management team's expertise to opportunistically in-license promising assets. Its most advanced product candidate, EIK1001, a toll-like receptor (TLR) 7/8 dual-agonist, is in a global Phase 2/3 registrational trial in combination with pembrolizumab for the treatment of patients with advanced melanoma. The company is led by Chair and Chief Executive Officer Dr. Roger M. Perlmutter, M.D., Ph.D., and Chief Medical Officer Dr. Roy Baynes, M.D., Ph.D., who have a track record of identifying, developing, and commercializing impactful drugs, including pembrolizumab. Its broader leadership team consists of former senior leaders at global pharmaceutical companies who have collaborated on the discovery, development, and commercialization of over 100 new molecular entities.

Eikon Therapeutics, Inc. (NASDAQ:EIKN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for EIKN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for EIKN spans 8-K, 10-Q, 10-K, SCHEDULE 13D.

Recent high-impact activity:

  • Eikon Posts $86.1M Q3 Loss, Cash Runway Extended Into Q1 2028
  • Eikon's EIK1001 Hits 63.1% ORR in First-Line NSCLC at ESMO 2026
  • Eikon Presents ESMO Data Across Three Programs, Including First Clinical Results for EIK1004 and EIK1005
  • Eikon Therapeutics Updates Corporate Presentation with New Clinical Data and Milestones
  • Eikon Therapeutics Q2 2026: Losses Continue, Material Weakness Unresolved

Short Interest & Short Volume

10.47 days to cover

FINRA reported short interest of 5,536,871 shares in EIKN as of the October 30, 2026 settlement, a 13.1% decrease from the prior period — about 10.5 days to cover at its recent average daily volume. On November 20, 2026, 61.3% of EIKN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)5,536,871 shares as of October 30, 2026
Change vs prior period▼ 13.1%
Days to cover10.47 at avg daily volume of 528,963
Daily short volume (FINRA facilities)61.3% of 226,412 shares on November 20, 2026
5-day average short volume68.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with E →
$4.74
52-week range · as of 2026-10-26 $4.74 – $17.4
Market cap
$256.84M
Volume
691.4K (1.3× avg)
3-mo avg 523.5K
Live data · 2026-11-21 00:33 UTC · After hours

show_chartPrice Chart

Loading chart...

feed EIKN - Latest Insights

EIKN
Nov 12, 2026, 6:30 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $6.66
Real-time Price: $4.74 info
Change: -$1.92 (-29%) info
Market Cap: $256.842M info
EIKN
Oct 26, 2026, 6:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.90
Real-time Price: $4.74 info
Change: -$2.16 (-31%) info
Market Cap: $256.842M info
EIKN
Oct 23, 2026, 9:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.24
Real-time Price: $4.74 info
Change: -$3.50 (-42%) info
Market Cap: $256.842M info
EIKN
Aug 13, 2026, 8:44 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.52
Real-time Price: $4.74 info
Change: -$5.78 (-55%) info
Market Cap: $256.842M info
EIKN
Aug 13, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $10.18
Real-time Price: $4.74 info
Change: -$5.44 (-53%) info
Market Cap: $256.842M info
EIKN
Aug 13, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.18
Real-time Price: $4.74 info
Change: -$5.44 (-53%) info
Market Cap: $256.842M info
EIKN
Jul 27, 2026, 10:22 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $9.80
Real-time Price: $4.74 info
Change: -$5.06 (-52%) info
Market Cap: $256.842M info
EIKN
Jun 01, 2026, 7:33 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $10.37
Real-time Price: $4.74 info
Change: -$5.63 (-54%) info
Market Cap: $256.842M info
EIKN
Jun 01, 2026, 7:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.37
Real-time Price: $4.74 info
Change: -$5.63 (-54%) info
Market Cap: $256.842M info
EIKN
May 11, 2026, 4:13 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.90
Real-time Price: $4.74 info
Change: -$5.16 (-52%) info
Market Cap: $256.842M info
EIKN
May 11, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.95
Real-time Price: $4.74 info
Change: -$5.21 (-52%) info
Market Cap: $256.842M info
EIKN
Mar 30, 2026, 9:51 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $9.94
Real-time Price: $4.74 info
Change: -$5.20 (-52%) info
Market Cap: $256.842M info
EIKN
Mar 30, 2026, 8:02 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $9.81
Real-time Price: $4.74 info
Change: -$5.07 (-52%) info
Market Cap: $256.842M info
EIKN
Mar 30, 2026, 7:50 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $9.81
Real-time Price: $4.74 info
Change: -$5.07 (-52%) info
Market Cap: $256.842M info
EIKN
Mar 30, 2026, 7:09 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $9.81
Real-time Price: $4.74 info
Change: -$5.07 (-52%) info
Market Cap: $256.842M info
EIKN
Feb 12, 2026, 6:48 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $14.83
Real-time Price: $4.74 info
Change: -$10.09 (-68%) info
Market Cap: $256.842M info
EIKN
Feb 10, 2026, 5:06 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $13.61
Real-time Price: $4.74 info
Change: -$8.87 (-65%) info
Market Cap: $256.842M info
EIKN
Feb 09, 2026, 9:19 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $15.62
Real-time Price: $4.74 info
Change: -$10.88 (-70%) info
Market Cap: $256.842M info
EIKN
Feb 06, 2026, 6:33 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $14.50
Real-time Price: $4.74 info
Change: -$9.76 (-67%) info
Market Cap: $256.842M info
EIKN
Feb 06, 2026, 6:25 PM EST
Filing Type: 4
Importance Score:
9
Price at Filing: $14.50
Real-time Price: $4.74 info
Change: -$9.76 (-67%) info
Market Cap: $256.842M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets